Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carlos Vallejo is active.

Publication


Featured researches published by Carlos Vallejo.


Journal of Clinical Oncology | 1994

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.

Alberto Romero; M. Rabinovich; Carlos Vallejo; J. E. Perez; R. Rodriguez; M A Cuevas; M. Machiavelli; J. Lacava; Mario J. Langhi; L Romero Acuña

PURPOSE A phase II trial was performed to evaluate the efficacy and toxicity of vinorelbine (VNB) as first-line chemotherapy for metastatic breast carcinoma. PATIENTS AND METHODS Between August 1991 and February 1993, 45 patients with metastatic breast cancer were entered onto the study. Therapy consisted of VNB 30 mg/m2 diluted in 500 mL of normal saline administered as a 1-hour intravenous infusion. Injections were repeated weekly until evidence of progressive disease (PD) or severe toxicity developed. RESULTS One patient was considered not assessable for response. An objective response (OR) was observed in 18 of 44 patients (41%; 95% confidence interval, 26% to 56%). Three patients (7%) had a complete response (CR) and 15 (34%) had a partial response (PR). The median time to treatment failure for the entire group was 6 months (range, 1 to 15), and the median duration of response was 9 months (range, 1 to 15). The median survival duration has not been reached yet. There were no treatment-related deaths. The dose-limiting toxicity was myelosuppression. Leukopenia occurred in 35 patients (78%) and was grade 3 or 4 in 16 (36%). Phlebitis was observed in 19 of 29 patients (66%) who did not have central implantable venous systems. Fifteen patients (33%) developed peripheral neurotoxicity. Myalgia occurred in 20 patients (44%). CONCLUSION VNB is an active drug against metastatic breast cancer with moderate toxicity, which justifies further evaluation in association with other agents.


British Journal of Cancer | 2000

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

A. Paradiso; Giovanni Simone; Stella Petroni; Bernardo Amadeo Leone; Carlos Vallejo; J. Lacava; Alberto Romero; M. Machiavelli; M De Lena; C J Allegra; Patrick G. Johnston

The purpose of this work was to analyse the ability of p53 and thymidilate synthase (TS) primary tumour expression to retrospectively predict clinical response to chemotherapy and long-term prognosis in patients with advanced colorectal cancers homogeneously treated by methotrexate (MTX)-modulated–5-fluorouracil (5-FU-FA). A total of 108 advanced colorectal cancer patients entered the present retrospective study. Immunohistochemical p53 (pAb 1801 mAb) and TS (TS106 mAb) expression on formalin-fixed paraffin-embedded primary tumour specimens was related to probability of clinical response to chemotherapy, time to progression and overall survival. p53 was expressed in 53/108 (49%) tumours, while 54/108 (50%) showed TS immunostaining. No relationship was demonstrated between p53 positivity and clinical response to chemotherapy (objective response (OR): 20% vs 23%, in p53+ and p53– cases respectively) or overall survival. Percent of OR was significantly higher in TS-negative with respect to TS-positive tumours (30% vs 15% respectively; P< 0.04); simultaneous analysis of TS and p53 indicated 7% OR for p53-positive/TS-positive tumours vs 46% for p53-positive/TS-negative tumours (P< 0.03). Logistic regression analysis confirmed a significant association between TS tumour status and clinical response to chemotherapy (hazard ratio (HR): 2.91; 95% confidence interval (CI) 8.34–1.01; two-sided P< 0.05). A multivariate analysis of overall survival showed that only a small number of metastatic sites was statistically relevant (HR 1.89; 95% CI 2.85–1.26; two-sided P< 0.03). Our study suggests that immunohistochemical expression of p53 and TS could assist the clinician in predicting response of colorectal cancer patients to modulated MTX-5-FU therapy.


International Journal of Cancer | 1999

Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer.

Joan Morote; Inés de Torres; Carme Caceres; Carlos Vallejo; Simó Schwartz; Jaume Reventós

It is well established that the activation of proto‐oncogenes could trigger uncontrolled cell growth and cancer development. Although this correlation has already been evidenced in several human tumors, no conclusive studies have related oncogene activation with the development of prostatic neoplasia. Nevertheless, some reports suggest that c‐erbB‐2, which is a prognostic marker in breast cancer, could be implicated in the development of prostatic adenocarcinoma. We have studied the expression of the c‐erbB‐2 oncoprotein in primary prostatic tissue in a series of 70 patients with metastasic disease, by means of immunohistochemistry. The NCL‐B 11 anti‐c‐erbB‐2 monoclonal antibody was used, and the immunoreactivity was quantified by image analysis. The overall rate of prostatic‐tissue sections presenting positive c‐erbB‐2 immunostaining was 64.3%. No significant relation was observed between histological grade and c‐erbB‐2 over‐expression or severity of the disease, based on the extent of metastases. The average specific survival in patients with c‐erbB‐2 over‐expression was 33 months, while it was 54 in patients with c‐erbB‐2 negativity; p < 0.034. These results, as well as the logistic‐regression analysis, suggest that expression of c‐erbB‐2 oncoprotein would be considered as an independent prognostic factor of metastatic prostate cancer. Moreover, it could discriminate between the prognosis of patients with Gleason score 2 to 7 and those with score 8 to 10. Our results suggest that the expression of c‐erbB‐2 oncoprotein in primary prostatic tissue could have a prognostic value in patients with metastatic prostate cancer. Int. J. Cancer (Pred. Oncol.) 84:421–425, 1999.


British Journal of Haematology | 2001

Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation

David Gallardo; Juan I. Aróstegui; A. Balas; Antonio Torres; Dolores Caballero; Enric Carreras; Salut Brunet; Antonio M. Jimenez; Rodolfo Mataix; David Serrano; Carlos Vallejo; Guillermo Sanz; Carlos Solano; Marta Rodríguez‐Luaces; J. Marín; Julio Baro; César Sanz; Jose Roman; Marcos González; Jaume Martorell; Jorge Sierra; Carmen Martín; Rafael de la Cámara; Albert Grañena

Disparity for the minor histocompatibility antigen HA‐1 between patient and donor has been associated with an increased risk of acute graft‐versus‐host disease (GvHD) after allogeneic human leucocyte antigen (HLA)‐identical sibling donor stem cell transplantation (SCT). However, no data concerning the impact of such disparity on chronic GvHD, relapse or overall survival are available. A retrospective multicentre study was performed on 215 HLA‐A2‐positive patients who received an HLA‐identical sibling SCT, in order to determine the differences in acute and chronic GvHD incidence on the basis of the presence or absence of the HA‐1 antigen mismatch. Disease‐free survival and overall survival were also analysed. We detected 34 patient–donor pairs mismatched for HA‐1 antigen (15·8%). Grades II–IV acute GvHD occurred in 51·6% of the HA‐1‐mismatched pairs compared with 37·1% of the non‐mismatched. The multivariate logistic regression model showed statistical significance (P: 0·035, OR: 2·96, 95% CI: 1·07–8·14). No differences were observed between the two groups for grades III–IV acute GvHD, chronic GvHD, disease‐free survival or overall survival. These results confirmed the association between HA‐1 mismatch and risk of mild acute GvHD, but HA‐1 mismatch was not associated with an increased incidence of chronic GvHD and did not affect relapse or overall survival.


American Journal of Clinical Oncology | 1988

Stage IV Breast Cancer: Clinical Course and Survival of Patients with Osseous Versus Extraosseous Metastases at Initial Diagnosis

Bernardo Amadeo Leone; Alberto Romero; M. G. Rabinovich; Carlos Vallejo; A. Bianco; J. E. Perez; M. Machiavelli; R. Rodriguez; L. A. Alvarez

The medical records of 414 patients with metastatic breast carcinoma treated between 1978 and 1986 were reviewed and 44 women were identified as having stage IV disease when the primary breast lesion was detected. Of these 44 women, 25 had metastatic disease limited to the skeleton while 19 had extraosseous lesions only. The clinical features, response to therapy, and survival were analyzed and compared for both groups. The median survival of those patients with bone-only metastases was 52 months as compared with 13 months for those with extraskeletal lesions (p = 0.0025). The response rate to first-line systemic therapy was similar for both groups (47% for bone metastases and 44% for extraosseous metastases). The median duration of response was 14 months (range, 3–55 months) for patients with bone disease and 8 months (range, 4–43 months) for those with extraskeletal lesions. We conclude that patients with metastatic breast cancer confined to the skeleton at initial diagnosis tend to follow an indolent, chronic course with prolonged survival. Therefore the increase in response rate with agressive chemotherapy should be balanced against its higher morbidity. Further studies are needed to confirm whether the better prognosis of these patients is determined by the anatomical confinement of the disease to the skeleton or merely reflects the influence of other prognostic factors.


International Journal of Cancer | 1996

p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long‐term prognosis

Angelo Paradiso; Mario Rabinovich; Carlos Vallejo; M. Machiavelli; Alberto Romero; Juan Perez; J. Lacava; Cuevas Ma; Ricardo Rodriquez; Bernardo Amadeo Leone; Maria Giovanna Sapia; Giovanni Simone; Mario De Lena

In a series of 71 patients with advanced colorectal cancer treated with biochemically modulated 5‐fluorouracil (5‐FU) and methotrexate (MTX), we investigated the relationship between the proliferating‐cell nuclear antigen (PCNA) (PC10) and p53 (Pab 1801) primary‐tumor immunohistochemical expression with respect to clinical response and long‐term prognosis. Nuclear p53 expression was demonstrated in 44% of samples (any number of positive tumor cells) while all tumors showed a certain degree of PCNA immunostaining. PCNA immunostaining was correlated with histopathologic grade and p53 expression, while p53 was not correlated with any of the parameters considered. The probability of clinical response to biochemically modulated 5‐FU was independent of p53 and PCNA expression. p53 expression (all cut‐off values) was not associated with short‐ or long‐term clinical prognosis, whereas patients with higher PCNA primary‐tumor expression showed longer survival from treatment and survival from diagnosis, according to univariate and multivariate analysis, particularly in the sub‐set of colon‐cancer patients. We conclude that the clinical response of advanced‐colorectal‐cancer patients to biochemically modulated 5‐FU and MTX cannot be predicted by PCNA and p53 primary‐tumor expression, but high PCNA expression appears to be independently related to long‐term prognosis.


Journal of Clinical Oncology | 1997

Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma

J. Lacava; Bernardo Amadeo Leone; M. Machiavelli; Alberto Romero; J. E. Perez; Y L Elem; R Ferreyra; G Focaccia; G Suttora; M A Salvadori; M A Cuevas; Luis A. Romero Acuña; J R Acuña; Mario J. Langhi; S Amato; J Castaldi; A Arroyo; Carlos Vallejo

PURPOSE To evaluate the efficacy and toxicity of vinorelbine (VNB) as single-agent neoadjuvant chemotherapy in advanced cervical carcinoma (ACC). PATIENTS AND METHODS Between December 1993 and October 1995, 43 untreated patients with stages IIB to IVA squamous cell cervical cancer were entered onto this study. Forty-two patients are assessable for response and 43 for toxicity. The median age was 46 years (range, 28 to 65). Distribution by stages (International Federation of Gynecology and Obstetrics [FIGO]) was as follows: IIB, 18 patients; IIIA, one; IIIB, 19; and IVA, five. Therapy consisted of VNB 30 mg/m2 by 20-minute intravenous (IV) infusion repeated weekly for 12 injections and followed by radical surgery if feasible or definitive radiotherapy. Both staging and response assessment were performed by a multidisciplinary team. RESULTS One patient was considered not assessable for response. A total of 493 cycles of therapy were administered and objective remissions were observed in 19 of 42 patients (45%; 95% confidence interval, 30% to 60%). Two patients (5%) had a complete response (CR) and 17 (40%) a partial response (PR); no change (NC) was observed in 16 (38%) and progressive disease (PD) in seven (17%). Six of 19 patients (32%) who achieved objective responses (ORs) underwent surgery. The median time to failure and median survival time have not been reached yet. There were no therapy-related deaths. The dose-limiting toxicity was myelosuppression. Leukopenia occurred in 35 patients (81%) and was grade 3 or 4 in seven (17%). Twelve patients (28%) developed peripheral neuropathy, while myalgias occurred in 10 (23%). Constipation was observed in nine patients (21%), one with a prolonged ileum. Phlebitis was recorded in 18 patients (41%). In contrast, emesis and mucositis were rarely observed. No patient developed alopecia grade 3. By the end of the twelfth course of treatment, the average received dose-intensity was 85.4% of that projected. CONCLUSION VNB is an active drug against ACC with moderate toxicity. Its activity is among the highest reported for single agents. Further evaluation in association with other agents is clearly justified.


American Journal of Clinical Oncology | 1990

Bone-Only Versus Visceral-Only Metastatic Pattern in Breast Cancer: Analysis of 150 Patients

J. E. Perez; M. Machiavelli; Bernardo Amadeo Leone; Alberto Romero; M. G. Rabinovich; Carlos Vallejo; A. Bianco; R. Rodriguez; M. A. Cuevas; L. A. Alvarez

The medical records of 510 patients with metastatic breast cancer were retrospectively reviewed. Seventy-seven patients with metastases confined to skeleton and 73 patients bearing visceral-only disease were identified. All patients had a disease-free interval ≤ months and received systemic therapy with any of the following modalities: chemotherapy, hormonotherapy, or chemohormonotherapy. The clinical features, response to treatment, and survival were analyzed and compared for both groups. Median survival of patients with osseous metastases was 28 months, while it was 13 months for those patients with a visceral pattern (p < 0.001). Response rates to first and second line systemic therapy for both metastatic patterns showed no significant differences, suggesting a similar degree of sensitivity or resistance in both groups. Objective regression to first therapy was 45% in the group with bony disease and 41% among patients with visceral involvement; median duration of response was 16 months and 13 months, respectively. In both groups progressive disease conserved the original metastatic pattern in most patients. We conclude that although a superiority in survival was evident for the osseous metastatic pattern, for these patients efforts should be made to select the least aggressive therapy in order to avoid excessive toxicity. Further studies are needed to confirm our findings.


Journal of Clinical Oncology | 1999

Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer

L. Romero Acuna; Mario J. Langhi; J. E. Perez; J. Romero Acuna; M. Machiavelli; J. Lacava; Carlos Vallejo; Alberto Romero; Hebe Margot Fasce; Eduardo Ortiz; S. Grasso; S. Amato; R. Rodriguez; M. Barbieri; Bernardo Amadeo Leone

PURPOSE To evaluate the efficacy and toxicity of a combination of vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy in metastatic breast carcinoma (MBC). PATIENTS AND METHODS Between August 1995 and August 1997, 49 patients with untreated MBC received a regimen that consisted of VNB 30 mg/m2 in a 20-minute intravenous (IV) infusion on days 1 and 8 and PTX 135 mg/m2 in a 3-hour IV infusion (starting 1 hour after VNB) on day 1. Cycles were repeated every 28 days. The median age of the patients was 52 years, and 59% of patients were postmenopausal. Median performance status was 1. Dominant sites of disease were soft tissue in 6%, bone in 29%, and viscera in 65%. RESULTS Objective responses were recorded in 27 of 45 assessable patients (60%; 95% confidence interval, 46% to 74%). Complete remissions occurred in three patients (7%), and partial remissions occurred in 24 patients (53%). No change was recorded in 12 patients (27%), and progressive disease occurred in six patients (13%). The median time to treatment failure was 7 months, and median survival duration was 17 months. The limiting toxicity was myelosuppression, mainly leukopenia in 49 patients (100%) (grade 1 to grade 2, four patients; grade 3, 30 patients; and grade 4, 15 patients). Neutropenia was observed in 100% of patients (grade 1 to grade 2, three patients; grade 3, 11 patients; grade 4, 35 patients). Two treatment-related deaths due to febrile neutropenia were observed in patients with massive liver involvement. Peripheral neurotoxicity developed in 33 patients (67%) (grade 1, 25 patients; grade 2, eight patients); there were no grade 3 or grade 4 episodes. CONCLUSION The combination of VNB-PTX showed significant activity as first-line chemotherapy for patients with MBC. Myelosuppression was the dose-limiting side effect, whereas neurotoxicity was mild to moderate.


Haematologica | 2009

Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study

David Gallardo; Rafael de la Cámara; José Nieto; Ildefonso Espigado; Arturo Iriondo; Antonio Jiménez-Velasco; Carlos Vallejo; Carmen Martín; Dolores Caballero; Salut Brunet; David Serrano; Carlos Solano; Josep Maria Ribera; Javier de la Rubia; Enric Carreras

The question of the relative efficacy of stem cell sources (bone marrow vs peripheral blood) for sibling allografts still remains, particularly in relation to quality of life. A study of a relatively homogeneous population has confirmed similar outcomes in terms of overall survival, transplant-related mortality or relapse incidence. However acute and chronic graft-vs-host disease showed increases in the peripheral blood group. Possibly as a consequence, although global quality of life did not differ, there was also a significant impairment of role and social functioning in this group. Background Granulocyte colony-stimulating factor mobilized peripheral blood stem cells are increasingly used instead of bone marrow as a stem cell source for transplantation. Whereas this change is almost complete for autologous transplantation, there are some concerns when considering allogeneic transplants. Design and Methods We performed a retrospective case-control study including 820 adult patients who had received an allogeneic stem cell transplant from an HLA-identical sibling donor. Quality of life (QoL) was assessed in 150 patients using the EORTC Quality of Life Questionnaire C30 (QLQ-C30). Results There were no statistically significant differences in overall survival at ten years (bone marrow: 48.9% vs. peripheral blood stem cells: 39.8%; p=0.621), transplant-related mortality (bone marrow: 28.9% vs. peripheral blood stem cells: 34.4%; p=0.682) or relapse incidence at 9 years (29.4% vs. 35.2%, respectively; p=0.688). Similar outcomes were maintained independently of the phase of the disease. However, multivariate analysis identified a higher incidence of acute graft-versus-host disease grades II-IV (p: 0.023; Hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.05–1.89) and grades III-IV (p: 0.006; HR: 1.89; 95% CI: 1.20–2.98), in the peripheral blood stem cells-stem cell transplant group. As previously described, extensive chronic graft-versus-host disease was also more frequent in the peripheral blood stem cells group (28% vs. 15.6%; p<0.001). Patients transplanted with peripheral blood stem cells had significant impairment of role and social functioning. Conclusions Although overall survival was not affected by the stem cell source, peripheral blood stem cell transplants were associated with a higher risk of both acute and chronic GvHD. Global quality of life was similar in both groups, but patients transplanted with peripheral blood stem cells showed worse role and social functioning scores, probably related to the increased incidence of chronic graft-versus-host disease.

Collaboration


Dive into the Carlos Vallejo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Isidro Jarque

Instituto Politécnico Nacional

View shared research outputs
Researchain Logo
Decentralizing Knowledge